{"id":20173,"date":"2023-03-30T00:24:00","date_gmt":"2023-03-29T16:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20173"},"modified":"2024-12-29T00:26:10","modified_gmt":"2024-12-28T16:26:10","slug":"harbour-biomed-reports-846-5-yoy-revenue-increase-and-expands-rd-in-2022-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20173","title":{"rendered":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials"},"content":{"rendered":"\n

Global biotechnology company Harbour BioMed (HKG: 2142<\/a>), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development (R&D) expenditure also saw a significant rise, reaching USD 135 million, up 26.2% YOY.<\/p>\n\n\n\n

Continued Clinical Development and Pipeline Advancements<\/strong>
Throughout 2022, Harbour BioMed persistently advanced its clinical development pipeline, including both externally licensed and internally discovered candidates. A key milestone was reached with the Phase III clinical trial for batolizumab, licensed from HanAll Biopharma for the treatment of myasthenia gravis, which successfully met its endpoints and is now poised for filing. The company’s internal pipeline also progressed, with ongoing global clinical development for the fully human anti-CTLA-4 antibody HBM4003, the B7H4 and 4-1BB-targeted HBM7008, and the TSLP monoclonal antibody (mAb) HBM9378. Additionally, HBM1020, HBM1022, and HBM1007 received Investigational New Drug (IND) approvals from the US FDA, with Harbour BioMed planning to submit at least one global IND application for its in-house products annually.<\/p>\n\n\n\n

Strategic Partnerships and Subsidiary Establishments<\/strong>
In 2022, Harbour BioMed forged partnerships with industry leaders such as AstraZeneca, Cullinan Oncology, CSPC Group, Kelun-Biotech, and Hualan Bio to bolster its pipeline products. The company also established a wholly-owned subsidiary, Nona Biosciences, to provide R&D solutions for next-generation antibodies and other biotherapeutic developments from discovery to the IND stage. Nona Biosciences secured several licensing deals with companies including Moderna and Dragonfly Therapeutics, contributing to the company’s significant revenue increase.<\/p>\n\n\n\n

Incubation of Early-Stage Projects and Financing Rounds<\/strong>
Harbour BioMed was actively involved in incubating early-stage projects in 2022. HBM Alpha Therapeutics (HBMAT), a joint venture with Boston Children’s Hospital affiliated with Harvard Medical School, completed a seed round of financing. Enkai Cell Technology, a technology platform incubation project, closed a RMB 100 million Series A financing round, continuing its exploration of the cutting-edge field of NK cell therapy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,190,916],"class_list":["post-20173","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-harbour-biomed","tag-hkg-2142"],"yoast_head":"\nHarbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development (R&D) expenditure also saw a significant rise, reaching USD 135 million, up 26.2% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20173\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20173\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-29T16:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T16:26:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials\",\"datePublished\":\"2023-03-29T16:24:00+00:00\",\"dateModified\":\"2024-12-28T16:26:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"Harbour BioMed\",\"HKG: 2142\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20173#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20173\",\"name\":\"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-29T16:24:00+00:00\",\"dateModified\":\"2024-12-28T16:26:10+00:00\",\"description\":\"Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development (R&D) expenditure also saw a significant rise, reaching USD 135 million, up 26.2% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20173\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20173#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials - Insight, China's Pharmaceutical Industry","description":"Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development (R&D) expenditure also saw a significant rise, reaching USD 135 million, up 26.2% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20173","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20173","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-29T16:24:00+00:00","article_modified_time":"2024-12-28T16:26:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20173#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20173"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials","datePublished":"2023-03-29T16:24:00+00:00","dateModified":"2024-12-28T16:26:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20173"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","Harbour BioMed","HKG: 2142"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20173#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20173","url":"https:\/\/flcube.com\/?p=20173","name":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-29T16:24:00+00:00","dateModified":"2024-12-28T16:26:10+00:00","description":"Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development (R&D) expenditure also saw a significant rise, reaching USD 135 million, up 26.2% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20173#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20173"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20173#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20173"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20173\/revisions"}],"predecessor-version":[{"id":20174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20173\/revisions\/20174"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}